In this study, we evaluated the ADAM17 inhibitory effects of CD, TQ, and m62A on cancer cells and constructed a visual drug-target-disease network to predict prospective targets and mechanisms of the anti-COVID-19 drugs using network pharmacology. This evidence concerns the gene ADAM17 and COVID-19.